The subtypes of peroxisome proliferator-activated receptors expressed by human podocytes and their role in decreasing podocyte injury

摘要: BACKGROUND AND PURPOSE Peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription factors, and three subtypes (α, β γ) have been identified. PPAR activation has reported to decrease renal injury markers of glomerular dysfunction in models ischemia/reperfusion (I/R). However, both the I/R effects agonists on podocytes, an integral cellular part filtration barrier, remain be established. EXPERIMENTAL APPROACH By using oxygen/glucose deprivation-reoxygenation as vitro model that mimics vivo I/R, podocyte death were compared. Human immortalized podocytes treated with gemfibrozil, GW0742, pioglitazone or rosiglitazone, a single repeated challenge. Cell loss, necrotic apoptotic cell measured. KEY RESULTS Only treatment each agonist significantly prevented death, mainly by decreasing apoptosis. In comparison, serum deprivation-induced apoptosis, treatments effective, although achieved more pronounced effect. Finally, our results showed preservation Bcl-2, Bax nephrin expression accompanied anti-apoptotic exerted human podocytes. CONCLUSION IMPLICATIONS These findings contribute clarification pathophysiological role PPARs suggest selective PPARα, PPARβ PPARγ may exert similar protective death.